title: A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.
abstract: OBJECTIVE
  Titanium-nitride-oxide-coated bioactive stents (BAS) have demonstrated a favourable outcome when compared with paclitaxel-eluting stents in patients with acute myocardial infarction (MI). In a prospective randomised non-inferiority study design, we compared the safety and efficacy of BAS versus everolimus-eluting stents (EES) in patients with acute coronary syndrome (ACS).
  
  
  RESULTS
  We randomised 827 patients with ACS (1:1) to either BAS (417) or EES (410). The primary endpoint was a composite of cardiac death, non-fatal MI or ischaemia-driven target lesion revascularisation (TLR) at 12-month follow-up. Analyses were performed by intention to treat. At 12-month follow-up, the primary composite endpoint occurred in 9.6% of patients in the BAS group and 9.0% of those in the EES group (HR [hazard ratio] 1.04, 95% CI [confidence interval] 0.81-1.32, p=0.81, p for non-inferiority =0.001). Non-fatal MI was significantly less frequent in the BAS as compared with the EES group (2.2% vs. 5.9%, p=0.007). However, the individual rates of cardiac death and ischaemia-driven TLR were similar between the two groups (1.9% vs. 1.0%, p=0.39, and 6.5% vs. 4.9%, p=0.37, respectively).
  
  
  CONCLUSIONS
  In patients presenting with ACS, BAS achieved a clinical outcome that was non-inferior to EES at 12-month follow-up.
authors: Heart Center, Satakunta Central Hospital, Pori, Finland. pasi.karjalainen@satshp.fi
authors: Pasi P
authors: PP
authors: Karjalainen
authors: Matti
authors: M
authors: Niemelä
authors: Juhani K E
authors: JK
authors: Airaksinen
authors: Fernando
authors: F
authors: Rivero-Crespo
authors: Hannu
authors: H
authors: Romppanen
authors: Jussi
authors: J
authors: Sia
authors: Jacques
authors: J
authors: Lalmand
authors: Bernard
authors: B
authors: de Bruyne
authors: Adam
authors: A
authors: Debelder
authors: Marc
authors: M
authors: Carlier
authors: Wail
authors: W
authors: Nammas
authors: Antti
authors: A
authors: Ylitalo
authors: Otto M
authors: OM
authors: Hess
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015607:Stents / Q000009:adverse effects; D014025:Titanium / Q000008:administration & dosage*
chemical_list: D010975:Platelet Aggregation Inhibitors; C434243:titanium-nitride-oxide; D000068338:Everolimus; D014025:Titanium; D020123:Sirolimus